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ABSTRACT 
Objective: The aim of this study was to carry out comparative dissolution studies with warfarin sodium reference tablets under the hydrodynamic 
environments generated by the USP basket and paddle apparatus and flow-through cell using different agitation rates and dissolution media. 
Methods: Dissolution profiles were obtained with the USP basket and paddle apparatus at 50, 75, and 100 rpm and 900 ml of water as dissolution 
medium. After this, dissolution profiles of warfarin sodium were obtained with the USP paddle apparatus and flow-through cell method using 0.1 N 
hydrochloric acid, acetate buffer pH 4.5, phosphate buffer pH 6.8, and water. Spectrophotometric determination at 308 nm was carried out during 
30 min. Dissolution profiles were compared with model-independent and model-dependent approaches. 
Results: Significant differences were found with mean dissolution time and dissolution efficiency at 50 and 75 rpm (*P<0.05). Makoid-Banakar was 
the best-fit model used to describe the in vitro release performance of warfarin sodium with 50-100 rpm and the USP basket and paddle 
apparatuses. Significant differences in all calculated parameters were found (*P<0.05) excepting percent dissolved at 30 min with 0.1 N 
hydrochloric acid and phosphate buffer pH 6.8. 
Conclusion: More research is necessary to identify the in vitro release performance of poorly soluble drugs under available USP apparatuses 
considering factors as agitation rate and kind of dissolution media. The knowledge of the in vitro release performance of reference drug products is 
important for the design of better generic formulations. 
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INTRODUCTION 
Warfarin is a colorless, crystalline compound with a melting point of 
151-161 °C. It is practically insoluble in water, readily soluble in acetone 
and dioxane, and moderately soluble in alcohols. The sodium salts are 
soluble in water but insoluble in organic solvents [1]. Warfarin is the 
most used oral anticoagulant; it prevents the formation of active 
coagulation factors II, VII, IX, and X in the liver by inhibiting the synthesis 
of coagulation factors [2]. The drug is indicated in the prophylaxis and 
treatment of venous thrombosis and pulmonary embolism, as well as in 
the prophylaxis and treatment of thromboembolic complications 
associated with atrial fibrillation and prosthetic valves [3]. Molecular 
structure of warfarin sodium is shown in fig. 1. 
 
 
Fig. 1: Molecular structure of warfarin sodium 
 
By its physicochemical characteristics and considering 
biopharmaceutic classification system criteria, warfarin has been 
classified as a class II drug (low solubility/high permeability) [4]. 
Absorption difficulties could be observed with drugs belonging to 
this class and in vitro release studies become an essential tool to 
identify those formulations with possible clinical problems. 
Pharmacopeial dissolution test for warfarin sodium tablets is described 
in United States Pharmacopoeia (USP) [5]. The method indicates the use 
of the USP paddle apparatus (USP Apparatus 2) at 50 rpm and 900 ml of 
water at 37.0±0.5 °C as dissolution medium. Under these conditions, not 
less than 80% must be dissolved at 30 min (Q = 80% at 30 min). To date, 
it has not been reported meaningful correlation between in vitro data 
using these conditions and in vivo results. 
On the other hand, although basket and paddle dissolution 
apparatuses are currently the most popular methods for many drug 
products, both methods are operated under closed finite sink 
conditions and cannot mimic the environment of the digestive 
system [6]. Several dissolution methods have been described in the 
USP; however, the selection of the appropriate method and data 
interpretation is not easily affordable due to the influence of 
technological differences and manufacturing process on the 
dissolution outcome [7]. The role of external hydrodynamics on the 
dissolution mechanism is still investigated because a fundamental 
understanding of the role of external hydrodynamic conditions on 
dissolution mechanisms is important [8]. 
The aim of this study was to evaluate the in vitro release performance 
of warfarin sodium tablets under the hydrodynamic environment 
generated by the USP basket apparatus (USP Apparatus 1), the USP 
paddle apparatus as well as the flow-through cell method (USP 
Apparatus 4), an apparatus that better simulates the gastrointestinal 
conditions of humans. Warfarin sodium tablets were tested with 0.1 N 
hydrochloric acid, acetate buffer pH 4.5 and phosphate buffer pH 6.8 
as dissolution media and the USP apparatuses above mentioned with 
different agitation rates. In vitro release studies involving these factors 
could support the design of better oral dosage forms, especially with 
poorly soluble drugs, as warfarin is. 
MATERIALS AND METHODS 
Formulation and chemicals 
Warfarin sodium tablets (Coumadin® 5-mg, Bristol-Myers Squibb 
Holdings Pharma LTD, Uxbridge, United Kingdom) were used. 
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Hydrochloric acid, sodium acetate, and phosphate monobasic and 
dibasic salts were supplied by J. T. Baker-Mexico (Xalostoc, Mexico). 
Warfarin sodium standard was purchased from Sigma-Aldrich Co. 
(St. Louis MO, USA). 
Content uniformity and assay 
Content uniformity and assay tests were performed according to the 
procedures described in the USP [5]. 
Analytical method validation 
Dissolution method was validated according to ICH guidelines [9]. 
Method linearity, accuracy, precision, and stability were evaluated. 
Linearity 
Three standard calibration curves of warfarin sodium in water were 
prepared (4 to 30 µg/ml) and the absorbance was measured at 308 
nm with 1 cm quartz cells. Absorbance vs. concentration data 
obtained were fitted by linear regression analysis and the 
coefficients of regression and the regression analysis of variance 
(ANOVA) were calculated. The response vs. warfarin sodium 
concentration proportionality was demonstrated by calculating the 
percentage relative standard deviation (RSD) of the response factor 
across the calibration curve range as follows:  RSD = (standard deviationmean ) × 100 Eq. 1 
Accuracy and precision 
To validate these parameters, the standard addition method was used, 
so that matrix effects can be easily removed. Twenty tablets were 
accurately weighed and crushed in a mortar; then, quantities of 
powder of warfarin sodium tablets plus a volume of an aqueous 
solution of warfarin sodium (1 mg/ml) to finally give the equivalent of 
50, 100, and 150% of the dose were dissolved in 900 ml of water at 
37.0±0.5 °C. The USP paddle apparatus at 50 rpm was used. At 30 min 
the amount of warfarin sodium dissolved in each vessel was calculated 
with reference to a standard calibration curve prepared on the day of 
the experiment. Each determination was performed in triplicate. The 
percentage relative error (RE) was taken as a measure of the accuracy 
and the RSD as a measure of precision. Experiments were carried out 
in three consecutive days. RE was calculated as follows:  RE = (found−addedadded ) × 100 Eq. 2 
Stability 
Drug stability was evaluated analyzing a solution of warfarin sodium 
prepared in water (5 µg/ml). This solution was analyzed at 0 h at 25 
°C and at 24, 48, and 72 h after stored at 4 and 25 °C. At 24, 48, and 
72 h (at each temperature) the percentage of absolute difference 
(AD) recovered of warfarin sodium was calculated as follows:  
AD = (initial−finalinitial ) × 100 Eq. 3 
Dissolution studies 
USP basket vs. USP paddle apparatus 
Dissolution profiles of warfarin sodium were determined in an 
automated USP basket and paddle apparatus (Sotax AT-7 Smart, 
Switzerland). An UV/Vis spectrophotometer with 1 mm flow cells 
(Perkin Elmer Lambda 35, USA) was used. All equipment and data 
generated were controlled by specific software designed by Sotax. 
Warfarin sodium tablets were sprinkled on 900 ml of water at 
37.0±0.5 °C as dissolution medium. With these USP apparatuses, the 
agitation rates of 50, 75, and 100 rpm were tested. Sequential 
sampling using 0.45 µm nitrocellulose filters (Millipore®) occurred 
over 30 min at regular 5 min intervals with 6 replicates. The amount 
of warfarin sodium dissolved was determined with a standard 
calibration curve at 308 nm. 
USP paddle apparatus vs. flow-through cell method 
Dissolution profiles of warfarin sodium tablets were obtained in an 
automated USP paddle apparatus at 50 rpm with 900 ml of 
dissolution medium and with a flow-through cell apparatus (Sotax 
CE6, Sotax AG, Switzerland) with 22.6 mm cells (i.d.). Laminar flow 
(with a bed of 6 g of glass beads) was used. The degassed dissolution 
media: 0.1 N hydrochloric acid, acetate buffer pH 4.5, phosphate 
buffer pH 6.8, and water at 37.0±0.5 °C were pumped at a flow rate 
of 16 ml/min. An open system was used without recycling the 
dissolution medium. Sequential sampling using nitrocellulose filters 
was set at regular 5 min intervals over 30 min, with 12 replicates. 
The amount of warfarin sodium dissolved was determined in an 
UV/Vis spectrophotometer with 1 mm quartz cells (Perkin Elmer 
Lambda 10, USA) at 308 nm. For every trial, a standard calibration 
curve was prepared. 
Data analysis 
Dissolution profiles of warfarin sodium were compared using 
model-independent and model-dependent methods. For model-
independent methods, mean dissolution time (MDT) and dissolution 
efficiency (DE) were calculated. Mean values were compared by a 
Student’s t-test and significant differences were considered if 
*P<0.05. For model-dependent comparisons, dissolution data were 
adjusted to hyperbola model and t50% and t80% data were calculated. 
Additionally, data were adjusted to different mathematical 
equations: Zero-order, First-order, Higuchi, Hixson-Crowell, Makoid-
Banakar and Weibull models were used. The model with the highest 
determination coefficient (R2adjusted) and the lowest Akaike 
Information Criterion (AIC) was chosen as the best-fit model [10]. 
Data analysis was carried out using the Excel add-in DDSolver 
program [11]. Mathematical equations used to fit warfarin sodium 
dissolution data are shown in table 1. 
 
Table 1: Mathematical equations used to fit dissolution data 
Model Equation 
Hyperbola 𝑦 = 𝑎𝑥𝑏 + 𝑥 
Zero-order 𝐹 = 𝑘0 ∙ 𝑡 
First-order 𝐹 = 100 ∙ (1 − 𝑒−𝑘1∙𝑡) 
Higuchi 𝐹 = 𝑘𝐻 ∙ 𝑡0.5 
Hixson-Crowell 𝐹 = 100 ∙ [1 − (1 − 𝑘𝐻𝐶 ∙ 𝑡)3] 
Makoid-Banakar 𝐹 = 𝑘𝑀𝐵 ∙ 𝑡𝑛 ∙ 𝑒−𝑘∙𝑡  
Weibull 𝐹 = 𝐹𝑚𝑎𝑥 ∙ (1 − 𝑒−(𝑡−𝑇𝑖)𝛽𝛼 ) 
 
RESULTS AND DISCUSSION 
Content uniformity and assay 
Warfarin sodium tablets were within USP limits. The percentages of 
warfarin sodium on the content uniformity test ranged from 101.66 
to 103.56% (official criteria is 85-115%) and the assay test 99.10% 
(official criteria is 90-110%). 
Linearity 
The mean regression equation from three standard calibration 
curves was: y = 0.0389x-0.0052. Linear regression was significant 
(R2 = 0.999; *P<0.05). The RSD value of the response factor was 
2.31%. 
Accuracy and precision 
To prove the accuracy and precision of the dissolution method, 
analysis of different dose percentages (50, 100, and 150%) was 
carried out on three different days (n = 3/d). The within-day and 
between-day precision and accuracy were calculated. Results are 
shown in table 2. The RSD obtained was in the range of 0.26 to 
5.13% and the RE was lower than 6.50%, which indicates a good 
accuracy and precision of the method. 
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Table 2: Accuracy and precision data of warfarin sodium 
 Within-day (n = 3) Between-day (n = 9) 
Added (mg) Found (mg) RSD (%) RE (%) Found (mg) RSD (%) RE (%) 
2.5 2.55±0.03 1.11 1.89 2.58±0.11 4.08 3.07 
5 5.22±0.03 0.53 4.37 5.26±0.09 1.77 5.24 




Stability of warfarin sodium in water was assessed analyzing a drug 
solution of 5 µg/ml at different times and temperatures. Absolute 
difference at 4 °C and 24, 48, and 72 h was 0.38, 0.50, and 0.84%, 
respectively. Values at 25 °C and the same sample times were 0.71, 
1.55, and 4.32%, respectively. Results suggest a good stability of 
warfarin sodium aqueous solution only at 4 °C for three consecutive 
days. 
USP basket vs. USP paddle apparatus 
Dissolution profiles of warfarin sodium tablets at different agitation 
rates and USP dissolution apparatuses are shown in fig. 2. 
 
 
Fig. 2: Dissolution profiles of warfarin sodium using different agitation rates and USP basket (USP 1) and paddle (USP 2) apparatuses. 
Mean, n = 6. Error bars were omitted for clarity 
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With the aim to compare the in vitro release performance of 
warfarin sodium under different agitation rates and USP 
apparatuses, common dissolution parameters were calculated. 
Results are shown in table 3. 
 
Table 3: Model-independent and-dependent parameters of warfarin sodium tablets 
Agitation rate (rpm) Parameter USP basket apparatus USP paddle apparatus 
50 Diss. at 30 min (%) 102.59±1.51 108.62±0.25* 
DE (%) 47.56±1.01 58.60±1.14* 
MDT (min) 16.09±0.18 13.82±0.29* 
t50% (min) 15.31±0.31 12.12±0.42* 
t80% (min) 24.50±0.49 20.54±0.44* 
75 Diss. at 30 min (%) 106.83±1.032 110.79±0.59* 
DE (%) 53.53±1.62 67.47±0.72* 
MDT (min) 14.98±0.35 11.73±0.22* 
t50% (min) 13.99±0.47 9.27±0.19* 
t80% (min) 22.28±0.57 17.16±0.27* 
100 Diss. at 30 min (%) 110.18±0.80 111.15±0.80 
DE (%) 61.97±1.36 62.87±1.15 
MDT (min) 13.13±0.32 13.03±0.26 
t50% (min) 11.31±0.38 11.03±0.27 
t80% (min) 19.33±0.51 19.01±0.43 
Mean±SEM, n = 6, *P<0.05 
 
Significant differences were found with all calculated parameters at 
50 and 75 rpm (*P<0.05). These differences were expected as both 
USP apparatuses generated different hydrodynamic environments 
that surrounded the dosage form. No significant differences at 100 
rpm were found (*P>0.05). Under this condition, the in vitro release 
performance of warfarin sodium obtained with the USP paddle 
apparatus can be considered equivalent to the release performance 
generated by the USP basket apparatus. 
For a complete comparison with a model-dependent approach, 
warfarin sodium dissolution data were adjusted to common 
mathematical equations. Results are shown in table 4. 
 
Table 4: Criteria used for the selection of the best-fit model 
Parameter Agitation rate 
(rpm) 





USP basket apparatus 
R2adjusted 50 0.9859  0.8301  0.7519  0.8862  0.9945  0.9675  
75 0.9891  0.8234  0.7833  0.8876  0.9908  0.9618  
100 0.9686  0.8274  0.8477  0.9001  0.9870  0.9404  
AIC 50 27.38  43.01  45.32  40.58  21.91  33.87  
75 24.86  43.85  45.10  41.13  24.40  35.45  
100 32.14  43.65 42.92  40.35  26.99  38.00  
USP paddle apparatus 
R2adjusted 50 0.9799  0.8563  0.8487  0.9222  0.9952  0.9676  
75 0.8990  0.8544  0.9104  0.9276  0.9936  0.9395  
100 0.9652  0.8256  0.8546  0.8989  0.9867  0.9328  
AIC 50 27.65  42.05  42.30  38.34  22.13  34.02  
75 39.49  41.83  38.91  37.62  22.65  37.41  
100 33.68  43.67  42.62  40.36  27.32  38.69  
Mean, n = 6 
 
According to the established criteria (higher R2adjusted and lower 
AIC) Makoid-Banakar equation was the best-fit model used to 
describe the in vitro release performance of warfarin sodium at 
50-100 rpm and the USP basket and paddle apparatuses. 
Parameters of this model and t50% data derived from the 
adjustment to this equation are shown in table 5. Significant 
differences were found between dissolution profiles at 50 and 75 
rpm (*P<0.05). 
 
Table 5: Makoid-Banakar parameters and t50% values derived from the adjustment to this mathematical model 
Agitation rate (rpm) kMB n k t50%±SEM (min) 
USP basket apparatus 
50 2.564  1.074  -0.004  16.28±0.35 
75 2.288  1.269  0.012  14.17±0.45 
100 3.171  1.275  0.023  11.47±0.33 
USP paddle apparatus 
50 3.480  1.140  0.014  12.16±0.39* 
75 4.682  1.168  0.026  9.50±0.15* 
100 3.535  1.253  0.022  11.20±0.23 
Mean, n = 6. *P<0.05 
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Fig. 3: Dissolution profiles of warfarin sodium with different dissolution media and USP paddle apparatus (USP 2) and flow-through cell 
method (USP 4). Mean, n = 12. Error bars were omitted for clarity 
 
USP paddle apparatus vs. flow-through cell method 
Dissolution profiles of warfarin sodium tablets with different USP 
apparatuses and dissolution media with physiological pH range are 
shown in fig. 3. 
At 30 min a limited dissolution of warfarin sodium with 0.1 N 
hydrochloric acid and acetate buffer pH 4.5 was found (<54%). For this 
result, only DE values were calculated. Better results were obtained with 
phosphate buffer pH 6.8 and water as dissolution media. Warfarin 
sodium tablets fulfilled the current pharmacopeial dissolution criteria (Q 
= 80% at 30 min). Pharmacopeial conditions were USP Apparatus 2 at 50 
rpm with 900 ml of water. For a complete comparison, model-
independent and model-dependent parameters were also calculated 
and statistically compared. Results are shown in table 6. 
Significant differences in all parameters were found (*P<0.05) 
accepting percentage dissolved at 30 min with 0.1 N 
hydrochloric acid and phosphate buffer pH 6.8. Results suggest a 
no-equivalence of the in vitro release performance of warfarin 
sodium between the USP paddle apparatus and flow-through cell 
method. Due to a limited dissolution of warfarin sodium with 0.1 
N hydrochloric acid and acetate buffer pH 4.5 only dissolution 
data with phosphate buffer pH 6.8 and water were adjusted to 
the mathematical models above described. Results are shown in 
table 7. 
Dissolution data of warfarin sodium generated by the USP paddle 
apparatus and flow-through cell method as well as phosphate buffer 
pH 6.8 and water were better described by the Makoid-Banakar 
model. Parameters of this model and t50% data derived from the 
adjustment to this equation are shown in table 8. Significant 
differences were found between dissolution profiles at pH 6.8 and 
water as dissolution media (*P<0.05). 
 
Table 6: Model-independent and model-dependent parameters of warfarin sodium tablets 
Medium Parameter USP paddle apparatus Flow-through cell method 
0.1 N HCl Diss. at 30 min (%) 10.25±1.60 13.16±1.20 
DE (%) 2.73±0.36 4.01±0.22* 
pH 4.5 Diss. at 30 min (%) 53.93±4.80 12.16±1.06* 
DE (%) 18.59±1.80 5.97±0.39* 
pH 6.8 Diss. at 30 min (%) 96.29±1.87 93.64±2.44 
DE (%) 54.72±1.70 42.23±1.12* 
MDT (min) 12.99±0.26 16.45±0.23* 
t50% (min) 12.65±0.58 17.15±0.38* 
t80% (min) 22.79±0.81 27.44±0.61* 
H2O Diss. at 30 min (%) 108.37±0.38 91.52±2.91* 
DE (%) 59.50±1.00 37.49±0.91* 
MDT (min) 13.53±0.25 17.67±0.16* 
t50% (min) 11.80±0.37 18.41±0.49* 
t80% (min) 20.19±0.38 29.45±0.79* 
Mean±SEM, n = 12, *P<0.05 
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Table 7: Criteria used for the selection of the best-fit model 









pH 6.8 R2adjusted 2 0.9499 0.9257 0.8810 0.9709 0.9977 0.9948 
4 0.9753 0.8439 0.7262 0.8917 0.9980 0.9851 
AIC 2 33.56 35.99 38.91 29.60 12.82 18.82 
4 29.95 41.80 45.32 39.51 15.76 27.26 
H2O R2adjusted 2 0.9693 0.8573 0.8554 0.9234 0.9952 0.9675 
4 0.9412 0.8025 0.6644 0.8482 0.9977 0.9835 
AIC 2 29.76 41.94 41.83 38.13 21.15 33.87 
4 35.87 43.32 46.63 41.70 13.47 27.13 
Mean, n = 12 
 
Table 8: Makoid-Banakar parameters and t50% values derived from the adjustment to this mathematical model 
Medium USP apparatus kMB n k t50%±SEM (min) 
pH 6.8 2 3.719  1.173  0.021  12.63±0.55 
4 0.924  1.487  0.014  11.85±0.36 
H2O 2 3.634  1.175  0.017  17.75±0.43* 
4 0.700  1.461  4.33E-4 19.93±0.34* 
Mean, n = 12. *P<0.05 
 
Differences among USP dissolution apparatuses can be considered 
expected as the hydrodynamic environment of each USP apparatus 
is different. It is necessary to know them to take advantage of these 
conditions, especially when a new oral dosage form is designed and 
is intended to evaluate it under certain conditions. It is important to 
carry out dissolution studies with reference drug products because 
it is known that the quality of generic formulations depends on 
extensive knowledge of the release performance of references under 
available USP apparatuses and media within the physiological pH 
range. Results agree with those found by Shabir [12], where in an 
evaluation of the USP basket and paddle apparatuses with atenolol 
generic tablets; the paddle method gave significantly better 
dissolution than the basket method. The found differences in the 
drug release of both methods were probably due to the differences 
in the basic design of these two apparatuses. The paddle apparatus 
makes it a better stirring device, which leads to faster dissolution 
rates when compared to the basket apparatus. The basket used in 
the rotating basket apparatus acts as a sample holder confining the 
dosage form in a relatively smooth flow of dissolution medium with 
minimal mechanical abrasion. This leads to slower dissolution rates 
when compared to the rotating paddle apparatus. 
Several authors agree with the importance of this kind of studies. 
Wu et al. [8] indicate that more detailed studies are needed to show 
the effect of the hydrodynamic environment on tablet dissolution 
rate processes and Shabir [12], working with a class III drug, found 
that the in vitro release rate of a hydrosoluble drug can be accurately 
controlled through choice of the USP apparatus used. On the other 
hand, Chevalier et al. [13] shown that the dissolution test can speed 
up the formulation development and identify a potential problem in 
drug release. Due to poor solubility, class II drugs are expected to 
have a dissolution-limited absorption and a meaningful IVIVC should 
be expected. Gao [6] found that the flow-through cell method may 
offer advantages for establishing a meaningful IVIVC since the flow-
through cell method better simulates the hydrodynamic 
environment of the gastrointestinal tract. Jinno et al. [14] and 
Jantratid et al. [15] have demonstrated that in vitro data obtained 
with the flow-through cell method better reflect the in vivo 
performance of drugs with solubility problems. 
Datta fitting to mathematical models above described was carried 
out without any physiological significance with the objective of find 
an equation that explains the in vitro release performance of 
warfarin sodium tablets. The purpose of using mathematical 
equations to fit dissolution data is that they facilitate the analysis 
and interpretation of release performance as a function of a few 
parameters that can be statistically compared [16]. In this work, 
under all dissolution conditions used, the mathematical equation 
that best describes the in vitro release of warfarin sodium is the 
Makoid-Banakar model. This model becomes identical to that of 
Korsmeyer-Peppas when the parameter k is equal to zero [17]. It 
follows the sole diffusion mechanism. The n function governs the 
shape of the dissolution curve [18]. 
Generic drugs are similar to brand-name drugs in terms of identity, 
strength, quality, purity, safety, potency, uses, and treatment. The 
belief that generic drugs are inferior to brand-name drugs has 
always been under debate, especially since the price of generic drugs 
is generally far cheaper than brand-name drugs [19]. To ensure the 
best quality of generic drugs, it is necessary to thoroughly evaluate 
the reference products and know the mechanism by which they 
release the drug under different circumstances. Generics with 
adequate quality can behave as brand-name products. 
Bioequivalence studies of warfarin sodium tablets (5-mg) with 
successful results were previously reported by several authors [20]. 
On the other hand, information about of novel anticoagulants 
different to heparin and warfarin was recently reported [21]. All 
these efforts are made to offer the population better pharmaceutical 
products. 
CONCLUSION 
More research is necessary to identify the in vitro release 
performance of poorly soluble drugs under available USP 
apparatuses considering factors as agitation rate and kind of 
dissolution media. Results of this work could be of interest to 
pharmaceutical laboratories to support the design of better oral 
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